GLP-1 Diabetes Drugs May Elevate Fracture Risk in Older Adults

New observational studies suggest GLP-1 medications used for Type 2 diabetes and obesity (e.g., Ozempic, Wegovy) may be linked to higher fracture risk in adults 65+, with increases in fragility fractures, osteoporosis, and gout signals. One study of about 46,000 seniors over ~3 years found an 11% higher fracture risk; another analysis reported a 29% higher osteoporosis risk over five years among GLP-1 users with obesity/diabetes. Causation isn’t established; rapid weight loss and nutritional changes may contribute to bone loss. Experts urge pre‑treatment bone-density screening and strategies to protect bone health, while noting GLP-1 benefits when used under medical supervision.